503 related articles for article (PubMed ID: 12060771)
1. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
[TBL] [Abstract][Full Text] [Related]
2. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.
Zimonjic DB; Pollock JL; Westervelt P; Popescu NC; Ley TJ
Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13306-11. PubMed ID: 11087871
[TBL] [Abstract][Full Text] [Related]
3. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
Westervelt P; Lane AA; Pollock JL; Oldfather K; Holt MS; Zimonjic DB; Popescu NC; DiPersio JF; Ley TJ
Blood; 2003 Sep; 102(5):1857-65. PubMed ID: 12750176
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
5. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
[TBL] [Abstract][Full Text] [Related]
6. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.
Pollock JL; Westervelt P; Kurichety AK; Pelicci PG; Grisolano JL; Ley TJ
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15103-8. PubMed ID: 10611345
[TBL] [Abstract][Full Text] [Related]
7. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.
Agrawal-Singh S; Koschmieder S; Gelsing S; Stocking C; Stehling M; Thiede C; Thoennissen NH; Köhler G; Valk PJ; Delwel R; Mills K; Bäumer N; Tickenbrock L; Hansen K; Berdel WE; Müller-Tidow C; Serve H
Blood; 2010 Jun; 115(22):4507-16. PubMed ID: 20215640
[TBL] [Abstract][Full Text] [Related]
8. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
[TBL] [Abstract][Full Text] [Related]
9. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
10. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
11. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
12. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
He LZ; Tribioli C; Rivi R; Peruzzi D; Pelicci PG; Soares V; Cattoretti G; Pandolfi PP
Proc Natl Acad Sci U S A; 1997 May; 94(10):5302-7. PubMed ID: 9144232
[TBL] [Abstract][Full Text] [Related]
13. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
14. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
15. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
[TBL] [Abstract][Full Text] [Related]
18. Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha.
Sukhai MA; Wu X; Xuan Y; Zhang T; Reis PP; Dubé K; Rego EM; Bhaumik M; Bailey DJ; Wells RA; Kamel-Reid S; Pandolfi PP
Oncogene; 2004 Jan; 23(3):665-78. PubMed ID: 14737102
[TBL] [Abstract][Full Text] [Related]
19. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
[TBL] [Abstract][Full Text] [Related]
20. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]